Evidence map›Paper›PMID 19497999›Full record

ReviewThe American journal of pathology2009

Emerging concepts in the pathogenesis of lung fibrosis.

William D Hardie, Stephan W Glasser, James S Hagood

Abstract readReview
In one paragraph

Review in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Non-steroid agents for idiopathic pulmonary fibrosis.The Cochrane database of systematic reviews · 2010
    Pooled it
  2. Trial
  3. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2015
    Trial
  4. Article
  5. Transcriptomic profiling of collagen gene expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026
    Article
  6. Review
  7. Review
  8. The critical role of LRG1 in pathological fibrosis.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  9. Rodent Models of Lung Disease: A Road Map for Translational Research.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Article
  12. Study on the changes of extracellular matrix morphology and components in COPD animal model by using lung decellularized scaffold.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  13. Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  14. Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets.International journal of biological sciences · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Anoctamin-1 is induced by TGF-β and contributes to lung myofibroblast differentiation.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

William D HardieDepartment of Pediatrics, Cincinnati Children's Medical Center, Cincinnati, Ohio, USA.
Stephan W Glasser
James S Hagood

Funding

SURFACTANT HOMEOSTASIS IN HEALTH AND DISEASEP01HL061646 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI WERT, SUSAN E · 1999 to 2008
$14.6M
Role of Surfactant Protein-C and Innate Lung DefenseR01HL050046 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI GLASSER, STEPHAN W. · 1999 to 2012
$3.9M
Regulation of Fibroblast Phenotype in Lung FibrosisR01HL082818 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAGOOD, JAMES S. · 2007 to 2017
$3.7M
Epidermal Growth Factor Receptor Activation in Pulmonary FibrosisR01HL086598 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI HARDIE, WILLIAM DAVID · 2007 to 2011
$2.1M
REGULATION OF THE LUNG SURFACTANT PROTEIN C GENER29HL050046 · NHLBI · CHILDREN'S HOSPITAL MED CTR (CINCINNATI) · PI GLASSER, STEPHAN W. · 1994 to 1998
–
NHLBI NIH HHS HL061646NHLBI NIH HHS HL 082818NHLBI NIH HHS HL086598NHLBI NIH HHS HL50046NHLBI NIH HHS P01 HL061646NHLBI NIH HHS R01 HL050046NHLBI NIH HHS R01 HL082818NHLBI NIH HHS R01 HL086598
6 · The paper itself

Abstract

Fibrogenesis is an often-deadly process with increasing world-wide incidence and limited therapeutic options. Pulmonary fibrogenesis involves remodeling of the distal airspace and parenchyma of the lung, and is characterized by excessive extracellular matrix deposition and accumulation of apoptosis-resistant myofibroblasts. Recent studies have added significantly to our understanding of the complex mechanisms involved in lung fibrogenesis. Emerging concepts in this field include the critical role of the epithelium, particularly type II pneumocytes, in the initiation and perpetuation of fibrosis in response to either endogenous or exogenous stress; a growing awareness of alternative activation of macrophages in tissue remodeling; growing appreciation of the alternative origins and phenotypic plasticity of fibroblasts; the roles of epigenetic reprogramming and context-dependent signaling in profibrotic phenotype alterations; and recognition of the importance of cross talk and convergence of intracellular signaling pathways. In vitro, in vivo, and in silico approaches support a paradigm of "disordered re-development" of the lung. Designing effective antifibrotic interventions will require accurate understanding of the complex interactions among the genetic, environmental, epigenetic, biochemical, cellular, and contextual abnormalities that promote pulmonary fibrogenesis.

Indexed as

AnimalsHumansPulmonary Fibrosis

Identifiers

PMID19497999
PMCPMC2708789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.